Current risks of transfusion-transmitted agents: A review

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 5, 2007, Pages 702-707

  Stramer, Susan L ^a  

^a AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; BACTERIUM CONTAMINATION; BACTERIUM DETECTION; BLOOD BANK; BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INFECTION RISK; REVIEW; SCREENING TEST; SEROLOGY; STATISTICAL MODEL; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

BACTERIAL INFECTIONS; BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; BLOOD DONORS; BLOOD-BORNE PATHOGENS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RISK FACTORS; VIRUS DISEASES;

EID: 34248399976     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative US blood donors by nucleic acid amplification testing. N Engl J Med. 2004;351:760-768.
2. Coste J, Reesink HW, Engelfriet CP, Laperche S. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang. 2005;88:289-303.
3. Center for Biologies Evaluation and Research. Bacterial contamination of platelets workshop. Bethesda, Md: US Food and Drug Administration; 1999. Available at: http://www.fda.gov/cber/minutes/workshop-min.htm. Accessed September 24, 1999.
4. American Association of Blood Banks. Guidance on Implementation of New Bacteria Reduction and Detection Standard. Bethesda, Md: AABB; August 29, 2003. Association Bulletin 03-10.
5. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-979.
6. Busch MP, Glynn SA, Wright DJ, et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion. 2005;45:1853-1863.
7. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45:254-264.
8. Jackson BR, Busch MP, Stramer SL, et al. The cost-effectiveness of NAT for HIV, HCV and HBV in whole-blood donations. Transfusion. 2003;43:721-729.
9. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion. 2003;43:788-798.
10. Dodd RY, Stramer SL. Indeterminate results in blood donor testing: what you don't know can hurt you. Transfus Med Rev. 2000;14:151-160.
11. Kleinman S, Busch MP, Hall L, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. JAMA. 1998;280:1080-1085.
12. Stramer SL. Viral diagnostics in the arena of blood donor screening. Vox Sang. 2004;87(suppl 2):S180-S183.
13. Delwart EL, Kalmin ND, Jones TS, et al. First case of HIV transmission by an RNA-screened blood donation. Vox Sang. 2004;86:771-777.
14. Phelps R, Robbins K, Liberti T, et al. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion. 2004;44:929-933.
15. Stramer SL, Chambers L, Page PL, et al. Third reported US case of HIV transmission from NAT screened blood [abstract]. Transfusion. 2003;43:40A. Abstract S134-040k.
16. Ferreira MC, Niel TJ. Differential transmission of human immunodeficiency virus (HIV) via blood components from an HIV-infected donor. Transfusion. 2006; 46:156-157.
17. Orton SL, Stramer SL, Dodd RY, Alter MJ. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion. 2004;44:275-281.
18. Peoples BG, Preston SB, Tzeng JL, et al. Prolonged antibody-negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient. Transfusion. 2000;40:1280-1281.
19. Durand F, Danic B, Tardivel R, et al. Discovery of a chronic HCV infection without seroconversion in a blood donor in France during 28 months. Transfus Clin Biol. 2000;7:242-250.
20. Schuttler CG, Caspari G, Jursch CA, et al. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA [letter]. Lancet. 2000;355:41-42.
21. Kleinman SH, Stramer SL, Brodsky JP, Caglioti S, Busch MP. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms. Transfusion. 2006;46:695-702.
22. Stramer SL. Pooled hepatitis B virus DNA testing by nucleic acid amplification testing: implementation or not. Transfusion. 2005;45:1242-1246.
23. Kleinman SH, Strong DM, Tegtmeier G, et al. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion. 2005;45:1247-1257.
24. Koppleman MH, Assal A, Chudy M, et al. Multicenter performance evaluation of a transcription mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C RNA and hepatitis B DNA in blood donations. Transfusion. 2005;45:1258-1266.
25. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States 2002. N Engl J Med. 2003;349: 1236-1245.
26. Dodd RY. Emerging infections, transfusion safety, and epidemiology. N Engl J Med. 2003;349:1205-1206.
27. Stramer SL, Custer B, Busch MP, Dodd RY. Strategies for testing blood donors for West Nile virus. Transfusion. 2006;46:2036-2037.
28. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353:451-459.
29. Busch MP, Caglioti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med. 2005; 353:460-467.
30. Custer B, Busch MP, Marfin AA, Petersen LR. The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med. 2005;143: 486-492.
31. Korves CT, Goldie SJ, Murray MB. Cost-effectiveness of alternative blood-screening strategies for West Nile virus in the United States. PLoS Med. 2006; 3(2)e21:0211-0221.
32. Kuehn BM. Studies propose targeted screening of blood for West Nile virus. JAMA. 2006;295:1235-1236.
33. Aubuchon JP. Meeting transfusion safety expectation. Ann Intern Med. 2005;143:537-538.
34. Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion. 2006;46: 272-277.
35. Ness PM, Lipton KS. Selective transfusion protocols: errors and accidents waiting to happen. Transfusion. 2001;41:713-715.
36. Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion. 2001;41:857-861.
37. Goldman M, Blajchman MA. Blood product-associated bacterial sepsis. Transfus Med Rev. 1991;V:73-83.
38. Kuehnert M, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41:1493-1499.
39. Fang CT, Chambers LA, Kennedy J, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion. 2005;45:1845-1852.
40. Eder AF, Kennedy JM, Dy B, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-6). Transfusion. 2007. In press.